MRT67307 (hydrochloride)
目录号 : GC49903A kinase inhibitor
Cas No.:2095432-39-4
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
MRT67307 is a kinase inhibitor that has been shown to inhibit TBK1, MARK1-4, IKKε, and NUAK1 (IC50 values are 19, 27-52, 160, and 230 nM, respectively), the salt-inducible kinases (SIKs; IC50s = 250, 67, and 430 nM for SIK1, SIK2, and SIK3, respectively) and ULK1 and ULK2 (IC50s = 45 and 38 nM, respectively).1,2,3,4 MRT67307 prevents the phosphorylation of IRF3 and the production of IFN-β and increases toll-like receptor-induced IL-10 and IL-1ra secretion in macrophages.1,3 Through its effects on ULK1 and ULK2, MRT67307 blocks autophagy.4
1.Clark, K., Peggie, M., Plater, L., et al.Novel cross-talk within the IKK family controls innate immunityBiochem. J.434(1)93-104(2011) 2.Clark, K., Takeuchi, O., Akira, S., et al.The TRAF-associated protein TANK facilitates cross-talk within the IkappaB kinase family during Toll-like receptor signalingProc. Natl. Acad. Sci. USA108(41)17093-17098(2011) 3.Clark, K., MacKenzie, K.F., Petkevicius, K., et al.Phosphorylation of CRTC3 by the salt-inducible kinases controls the interconversion of classically activated and regulatory macrophagesProc. Natl. Acad. Sci. USA109(42)16986-16991(2012) 4.Petherick, K.J., Conway, O.J.L., Mpamhanga, C., et al.Pharmacological inhibition of ULK1 kinase blocks mammalian target of rapamycin (mTOR)-dependent autophagyJ. Biol. Chem.290(18)11376-11383(2015)
Cas No. | 2095432-39-4 | SDF | Download SDF |
Canonical SMILES | O=C(C1CCC1)NCCCNC2=NC(NC3=CC(CN4CCOCC4)=CC=C3)=NC=C2C5CC5.Cl | ||
分子式 | C26H36N6O2 • XHCl | 分子量 | 464.6 |
溶解度 | DMF: 5 mg/ml,DMF:PBS (pH 7.2) (1:5): 0.16 mg/ml,DMSO: 3 mg/ml,Ethanol: 2 mg/ml | 储存条件 | -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.1524 mL | 10.7619 mL | 21.5239 mL |
5 mM | 0.4305 mL | 2.1524 mL | 4.3048 mL |
10 mM | 0.2152 mL | 1.0762 mL | 2.1524 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。